Table 2.

Characteristics of the patients grouped immune cells and peripheral blood.

Variables	NLR		P	PLR		P	LMR		P	CD3		P	CD4		P	CD8		P
	<2.00	≥2.00		<117.60	≥117.60		<4.02	≥4.02		<93.5	≥93.5		<56.5	≥56.5		<54.5	≥54.5
Age (year)
<60	20	16	0.001	19	17	0.370	20	16	0.175	16	20	0.358	19	17	0.646	22	14	0.066
≥60	7	33		17	23		16	24		22	18		19	21		16	24
Gender
Male	18	23	0.512	21	20	0.467	18	23	0.512	18	23	0.250	21	20	0.818	23	18	0.198
Female	9	26		15	20		18	17		20	15		17	18		15	20
Tumor stage
T1-T2	16	16	0.025	17	15	0.391	5	27	0.003	9	23	0.001	18	14	0.691	9	23	0.001
T3-T4	11	33		19	25		31	13		29	15		20	24		29	15
Lymph node metastasis
No	18	33	0.952	23	28	0.571	23	28	0.571	19	32	0.002	26	25	0.807	18	33	0.001
Yes	9	16		13	12		13	12		19	6		12	13		20	5
Bismuth-Coretre type
I-II	16	17	0.039	17	16	0.526	16	17	0.864	11	22	0.011	13	20	0.105	12	21	0.025
III-IV	11	32		19	24		20	23		27	16		25	18		26	17
Tumor differentiation
Moderate/poor	23	42	0.949	34	31	0.036	30	35	0.606	33	32	0.744	31	34	0.328	33	32	0.744
well	4	7		2	9		6	5		5	6		7	4		5	6
Tumor size (cm)
<3	19	31	0.532	22	28	0.015	26	24	0.262	26	24	0.472	23	27	0.231	25	25	0.688
≥3	8	18		16	10		10	16		12	14		16	10		13	13
Liver invasion
No	22	41	1.000	29	34	0.607	30	33	0.923	33	30	0.361	29	34	0.128	29	34	0.128
Yes	5	8		7	6		6	7		5	8		9	4		9	4
Neural invasion
No	8	14	0.922	8	14	0.220	13	9	0.191	8	14	0.129	12	10	0.613	7	15	0.052
Yes	19	35		28	26		23	31		30	24		26	28		31	23
Portal vein invasion
No	16	21	0.171	17	20	0.809	13	24	0.037	11	26	0.001	18	19	0.818	12	25	0.002
Yes	11	28		19	20		23	16		27	12		20	19		26	13
CEA (ng/ml)
<5.0	22	43	0.457	30	35	0.486	34	31	0.036	32	33	0.744	32	33	0.744	34	31	0.328
≥5.0	5	6		6	5		2	9		6	5		6	5		4	7
CA19-9 (U/ml)
<37	13	12	0.035	14	11	0.291	16	9	0.052	8	17	0.028	14	11	0.464	7	18	0.007
≥37	14	37		22	29		20	31		30	21		24	27		31	20
Total bilirubin(μmol/L)
<34.2	4	9	0.693	7	6	0.546	8	5	0.261	3	10	0.033	9	4	0.128	7	6	0.761
≥34.2	23	40		29	34		28	35		35	28		29	34		31	32

CEA, carcinoembryonic antigen; CA, 19-9 cancer antigen 19-9; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; LMR, lymphocyte monocyte ratio.